Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBER: Prolonged Bivalirudin After Elective PCI
NCT04120961Completed
- Sponsor
- Nanjing First Hospital
- Start
- Sep 2019
- Primary completion
- Aug 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of bivalirudin in coronary heart disease (CHD) (2 arms), sponsored by Nanjing First Hospital. Primary endpoint: Incidence rate of Peri-operative Myocardial Injury at 3 days. Started Sep 2019; status: completed.
02
Drugs
bivalirudin
03
Conditions
coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT04120961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04120961.